By using bispecific antibodies targeting a tumor-associated antigen (TAA) on the cancer cells, and CD3 on the T-cells, it is possible to redirect and activate any circulating T-cells against tumor cells independently of the specificity of their TCR. Thanks to the bridging action of such TAAxCD3 bsAb, T-cells are brought in close proximity of the target cancer cells, leading to subsequent T-cell activation and T-cell–mediated killing of the tumor cells.
For more information on T-cell redirecting κλ-bodies, please visit Light Chain Bioscience.
Read our latest news
Cytotoxic Drug Development Application Note
Discover how Nanolive’s LIVE Cytotoxicity Assay transforms cytotoxic drug development through high-resolution, label-free quantification of cell health and death. Our application note explores how this advanced technology enables real-time monitoring of cell death...
Investigative Toxicology Application Note
Our groundbreaking approach offers a label-free, high-content imaging solution that transforms the way cellular health, death, and phenotypic responses are monitored and quantified. Unlike traditional cytotoxicity assays, Nanolive’s technology bypasses the limitations...
Phenotypic Cell Health and Stress Application Note
Discover the advanced capabilities of Nanolive’s LIVE Cytotoxicity Assay in an application note. This document presents a detailed exploration of how our innovative, label-free technology enables researchers to monitor phenotypic changes and detect cell stress...
Nanolive microscopes
3D CELL EXPLORER
Budget-friendly, easy-to-use, compact solution for high quality non-invasive 4D live cell imaging
3D CELL EXPLORER-fluo
Multimodal Complete Solution: combine high quality non-invasive 4D live cell imaging with fluorescence
CX-A
Automated live cell imaging: a unique walk-away solution for long-term live cell imaging of single cells and cell populations